Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

TGFβ signaling in myeloid cells regulates mammary carcinoma cell invasion through fibroblast interactions.

Shaw AK, Pickup MW, Chytil A, Aakre M, Owens P, Moses HL, Novitskiy SV.

PLoS One. 2015 Jan 28;10(1):e0117908. doi: 10.1371/journal.pone.0117908. eCollection 2015.

2.

Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis.

Novitskiy SV, Forrester E, Pickup MW, Gorska AE, Chytil A, Aakre M, Polosukhina D, Owens P, Yusupova DR, Zhao Z, Ye F, Shyr Y, Moses HL.

Breast Cancer Res. 2014 Oct 4;16(5):425. doi: 10.1186/s13058-014-0425-7.

3.

A novel TTC40-MSI2 fusion in de novo acute myeloid leukemia with an unbalanced 10;17 translocation.

Saleki R, Christensen T, Liu W, Wang X, Chen QC, Aakre M, Gomes NM, Alexiev BA, Schappert J, Baer MR, Zou YS.

Leuk Lymphoma. 2015 Apr;56(4):1137-9. doi: 10.3109/10428194.2014.947611. Epub 2014 Aug 20. No abstract available.

4.

Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas.

Pickup MW, Laklai H, Acerbi I, Owens P, Gorska AE, Chytil A, Aakre M, Weaver VM, Moses HL.

Cancer Res. 2013 Sep 1;73(17):5336-46. doi: 10.1158/0008-5472.CAN-13-0012. Epub 2013 Jul 15.

5.

Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk.

Matise LA, Palmer TD, Ashby WJ, Nashabi A, Chytil A, Aakre M, Pickup MW, Gorska AE, Zijlstra A, Moses HL.

Breast Cancer Res. 2012 Jul 2;14(4):R98. doi: 10.1186/bcr3217.

6.

TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms.

Novitskiy SV, Pickup MW, Gorska AE, Owens P, Chytil A, Aakre M, Wu H, Shyr Y, Moses HL.

Cancer Discov. 2011 Oct;1(5):430-41. doi: 10.1158/2159-8290.CD-11-0100.

7.

Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.

Ijichi H, Chytil A, Gorska AE, Aakre ME, Bierie B, Tada M, Mohri D, Miyabayashi K, Asaoka Y, Maeda S, Ikenoue T, Tateishi K, Wright CV, Koike K, Omata M, Moses HL.

J Clin Invest. 2011 Oct;121(10):4106-17. doi: 10.1172/JCI42754. Epub 2011 Sep 19.

8.

Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators.

Owens P, Pickup MW, Novitskiy SV, Chytil A, Gorska AE, Aakre ME, West J, Moses HL.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2814-9. doi: 10.1073/pnas.1101139108. Epub 2011 May 16.

9.

Quantitative analysis of the secretome of TGF-beta signaling-deficient mammary fibroblasts.

Xu BJ, Yan W, Jovanovic B, An AQ, Cheng N, Aakre ME, Yi Y, Eng J, Link AJ, Moses HL.

Proteomics. 2010 Jul;10(13):2458-70. doi: 10.1002/pmic.200900701.

10.

Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer.

Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, Aakre M, Shyr Y, Moses HL.

J Clin Invest. 2009 Jun;119(6):1571-82. doi: 10.1172/JCI37480. Epub 2009 May 18.

11.

GFAP-Cre-mediated activation of oncogenic K-ras results in expansion of the subventricular zone and infiltrating glioma.

Abel TW, Clark C, Bierie B, Chytil A, Aakre M, Gorska A, Moses HL.

Mol Cancer Res. 2009 May;7(5):645-53. doi: 10.1158/1541-7786.MCR-08-0477. Epub 2009 May 12.

12.

Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.

Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, Aakre M, Forrester E, Yang L, Wagner KU, Moses HL.

Cancer Res. 2008 Mar 15;68(6):1809-19. doi: 10.1158/0008-5472.CAN-07-5597.

13.

Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis.

Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, Moses HL.

Cancer Cell. 2008 Jan;13(1):23-35. doi: 10.1016/j.ccr.2007.12.004.

14.

Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells.

Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, Moses HL, Cheng N.

Cancer Biol Ther. 2007 Apr;6(4):561-70.

15.
16.
17.

Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro.

Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL.

Neoplasia. 2004 Sep-Oct;6(5):603-10.

18.

Construction of a cyclin D1-Cdk2 fusion protein to model the biological functions of cyclin D1-Cdk2 complexes.

Chytil A, Waltner-Law M, West R, Friedman D, Aakre M, Barker D, Law B.

J Biol Chem. 2004 Nov 12;279(46):47688-98. Epub 2004 Sep 7.

19.

Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro.

Brown KA, Aakre ME, Gorska AE, Price JO, Eltom SE, Pietenpol JA, Moses HL.

Breast Cancer Res. 2004;6(3):R215-31. Epub 2004 Mar 17.

20.

TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest.

Bhowmick NA, Ghiassi M, Aakre M, Brown K, Singh V, Moses HL.

Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15548-53. Epub 2003 Dec 1.

21.

Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line.

Xie L, Law BK, Aakre ME, Edgerton M, Shyr Y, Bhowmick NA, Moses HL.

Breast Cancer Res. 2003;5(6):R187-98. Epub 2003 Aug 20.

23.

Transforming growth factor beta mimetics: discovery of 7-[4-(4-cyanophenyl)phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase.

Glaser KB, Li J, Aakre ME, Morgan DW, Sheppard G, Stewart KD, Pollock J, Lee P, O'Connor CZ, Anderson SN, Mussatto DJ, Wegner CW, Moses HL.

Mol Cancer Ther. 2002 Aug;1(10):759-68.

24.

Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells.

Law BK, Chytil A, Dumont N, Hamilton EG, Waltner-Law ME, Aakre ME, Covington C, Moses HL.

Mol Cell Biol. 2002 Dec;22(23):8184-98.

26.

Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism.

Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL.

Mol Biol Cell. 2001 Jan;12(1):27-36.

27.

Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen.

Law BK, Waltner-Law ME, Entingh AJ, Chytil A, Aakre ME, Nørgaard P, Moses HL.

J Biol Chem. 2000 Dec 8;275(49):38261-7.

28.
29.

Inhibition of cell growth by TGF beta 1 is associated with inhibition of B-myb and cyclin A in both BALB/MK and Mv1Lu cells.

Satterwhite DJ, Aakre ME, Gorska AE, Moses HL.

Cell Growth Differ. 1994 Aug;5(8):789-99.

30.

[Why do we push for hospices in Norway?].

Aakre M.

Sykepleien. 1989 Apr 20;77(7):4-6, 23. Norwegian. No abstract available.

PMID:
2749539
31.

[After 1 year with primary nursing: we will not go back to the team system].

Strand T, Aakre M.

Sykepleien. 1984 Nov 20;71(20):6-10, 28. Norwegian. No abstract available.

PMID:
6084873
32.

[Cross-professional advisory group in terminal care].

Eilertsen ME, Opdahl Mo ES, Aakre M.

Sykepleien. 1982 Jul 5;69(12):16-7. Norwegian. No abstract available.

PMID:
6923554

Supplemental Content

Support Center